Morgan Stanley Resumes Akebia Therapeutics (AKBA) at Equalweight
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Price: $0.84 -3.45%
Rating Summary:
12 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
12 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
Morgan Stanley analyst David Lebowitz resumes coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Equalweight rating and a price target of $9.00.
For an analyst ratings summary and ratings history on Akebia Therapeutics click here. For more ratings news on Akebia Therapeutics click here.
Shares of Akebia Therapeutics closed at $7.93 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Citi Resumes Universal Music Group NV (UMG:NA) (UMGNF) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
